Novo Nordisk A/S $NVO Stake Lifted by Pekin Hardy Strauss Inc.

Key Points

• Pekin Hardy Strauss increased its Novo Nordisk stake by 134.7% in the third quarter, adding 94,513 shares and bringing its holdings to 164,673 shares, valued at about $6.24 million.
• Other institutions also added to or initiated positions, while institutional investors collectively own 11.54% of the stock.
• Novo reported better-than-expected third-quarter results and raised its 2026 outlook, supported by GLP-1 demand; however, shares fell 4.5%, and analysts’ consensus rating remains Hold.

Pekin Hardy Strauss Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 134.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 164,673 shares of the company's stock after acquiring an additional 94,513 shares during the period. Pekin Hardy Strauss Inc.'s holdings in Novo Nordisk A/S were worth $6,243,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Novo Nordisk A/S by 2,414.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company's stock worth $14,280,000 after buying an additional 286,034 shares during the last quarter. Trust Co. of Vermont bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $1,250,000. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $2,324,000. Myriad Asset Management Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $1,846,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Novo Nordisk A/S by 22.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 229,607 shares of the company's stock valued at $11,007,000 after buying an additional 42,361 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Third-quarter results beat expectations: adjusted sales were DKK 79.2 billion, obesity sales grew 22%, and adjusted operating profit increased 27%. Novo raised its full-year 2026 outlook, citing demand for its GLP-1 portfolio. Reuters: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: Wegovy pill adoption exceeded management’s expectations and came in ahead of forecasts, bolstering the growth outlook. Novo plans to expand the pill into more than 20 markets by mid-2027. BioPharma Dive: Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
• Positive Sentiment: Novo and Abbott are expanding their diabetes-drug collaboration in Asia, potentially supporting wider regional reach. MarketScreener: Abbott and Novo Nordisk expand collaboration on diabetes drug in Asia
• Neutral Sentiment: The company did not provide 2027 guidance. Management cited factors that could help or hinder next year’s sales, leaving investors without a firm near-term growth target. The Motley Fool: Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance
• Negative Sentiment: Despite solid sales, coverage highlights a squeeze on profits, while impairment charges weighed on reported operating profit. Pricing pressure and questions about future margins may be tempering enthusiasm for the outlook. Yahoo Finance: Novo Nordisk Stock Faces Q3 Earnings Profit Squeeze
• Negative Sentiment: CFO Karsten Munk Knudsen is leaving the company. The upcoming handover adds a management transition as investors assess the earnings and outlook. Reuters: Novo Nordisk's CFO Karsten Munk Knudsen to leave company

Novo Nordisk A/S Trading Down 4.5%

Shares of NVO stock opened at $40.29 on Friday. The company's fifty day simple moving average is $40.70 and its two-hundred day simple moving average is $43.96. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The stock has a market capitalization of $179.89 billion, a price-to-earnings ratio of 10.15, a PEG ratio of 1.42 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 54.22% and a net margin of 33.99%. The firm had revenue of $11.98 billion for the quarter. As a group, analysts anticipate that Novo Nordisk A/S will post 3.44 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. BMO Capital Markets set a $40.00 price target on Novo Nordisk A/S and gave the stock a "market perform" rating in a research note on Monday, October 12th. Berenberg Bank reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Barclays restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Cfra downgraded shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating and set a $38.00 price objective on the stock. in a report on Tuesday, September 22nd. Finally, HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a research report on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.